(2E)-3-苯基-N-[1-羟基-2,2,2-三氯乙基]-2-丙烯酰胺 | 16535-67-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: (2E)-3-苯基-N-[1-羟基-2,2,2-三氯乙基]-2-丙烯酰胺
• 英文名称: (2E)-3-phenyl-N-[1-hydroxy-2,2,2-trichloroethyl]-2-acrylamide
• 英文别名: (2E)-3-phenyl-N-[1-hydroxy-2,2,2-trichloroethyl]acrylamide；(2E)-N-(1-hydroxy-2,2,2-trichloroethyl)-3-phenylacrylamide；3-Phenyl-N-(2,2,2-trichloro-1-hydroxyethyl)acrylamide；(E)-3-phenyl-N-(2,2,2-trichloro-1-hydroxyethyl)prop-2-enamide
• CAS: 16535-67-4
• 化学式: C₁₁H₁₀Cl₃NO₂
• 分子量: 294.565
• InChiKey: HHBQQDDALDBXDX-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  (2E)-3-苯基-N-[1-羟基-2,2,2-三氯乙基]-2-丙烯酰胺 在 氯化亚砜 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 26.0h， 生成 (E)-3-phenyl-N-[2,2,2-trichloro-1-[[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]amino]ethyl]prop-2-enamide
  参考文献：
  名称：

  SAR, Cardiac Myocytes Protection Activity and 3D-QSAR Studies of Salubrinal and its Potent Derivatives

  摘要：

  DOI：

  10.2174/092986712804485971
• 作为产物：
  描述：

  3-苯基-2-丙烯酰氯 在 ammonium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 反应 4.0h， 生成 (2E)-3-苯基-N-[1-羟基-2,2,2-三氯乙基]-2-丙烯酰胺
  参考文献：
  名称：

  SAR, Cardiac Myocytes Protection Activity and 3D-QSAR Studies of Salubrinal and its Potent Derivatives

  摘要：

  DOI：

  10.2174/092986712804485971

文献信息

• [EN] TARGETING OF ENDOPLASMIC RETICULUM DYSFUNCTION AND PROTEIN FOLDING STRESS TO TREAT NEUROLOGICAL CONDITIONS<br/>[FR] CIBLAGE D'UN DYSFONCTIONNEMENT DU RÉTICULUM ENDOPLASMIQUE ET D'UN STRESS DE REPLIEMENT PROTÉIQUE POUR TRAITER DES AFFECTIONS NEUROLOGIQUES
  申请人：ALS THERAPY DEVELOPMENT INST

  公开号：WO2019182698A1

  公开（公告）日：2019-09-26

  Methods and therapeutic compositions are disclosed for treating neurological disorders, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Parkinson's disease and/or Huntington's disease, using Salubrinal analogs, or pharmaceutically acceptable salts, hydrates, or solvates thereof.

  本发明揭示了使用Salubrinal类似物或其药学上可接受的盐、水合物或溶剂，治疗神经系统疾病，例如肌萎缩性侧索硬化症（ALS）、阿尔茨海默病、帕金森病和/或亨廷顿病的方法和治疗组合物。
• Thiazole Compounds and Uses Thereof
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

  公开号：US20150119430A1

  公开（公告）日：2015-04-30

  The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.

  本发明涉及一种式（I）的化合物，或其异构体，药学上可接受的盐和溶剂化物；本发明进一步涉及一种药物组合物，该药物组合物包括式（I）的化合物，或其异构体，药学上可接受的盐或溶剂化物，以及药学上可接受的载体、赋形剂或稀释剂；本发明进一步涉及使用式（I）的化合物，或其异构体，药学上可接受的盐或溶剂化物，用于抗凋亡、预防或治疗与凋亡相关的疾病或症状，特别是用于保护心肌细胞，以及预防或治疗与心肌细胞凋亡相关的疾病或症状。
• Novel Urea Compounds, Preparation Methods and Uses Thereof
  申请人：INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA

  公开号：US20160311767A1

  公开（公告）日：2016-10-27

  The invention provides a compound of Formula I, an isomer, a pharmaceutically acceptable salt, or a solvate thereof, and use thereof in manufacture of a medicament for preventing and/or treating a drug-resistant tumor or disease or disorder caused by a drug-resistant bacterium, or use thereof in manufacture of a medicament for preventing and/or treating a tumor, a neurodegenerative disease, an allogeneic graft rejection, or an infection-associated disease or disorder; preferably, the tumor, neurodegenerative disease, allogeneic graft rejection, or infection-associated disease or disorder is a disease or disorder caused by Heat shock protein 70 (Hsp70). The compounds of the invention, which are a class of Hsp70 inhibitors having a novel structure and a high activity, solve the problem concerning drug resistance of tumors, enhance the effect of treating tumors, and provide a new medical strategy for treatment of tumors in clinic.

  本发明提供了一种公式I的化合物、其异构体、药学上可接受的盐或其溶剂，以及在制造用于预防和/或治疗耐药肿瘤或由耐药细菌引起的疾病或紊乱的药物中的使用，或在制造用于预防和/或治疗肿瘤、神经退行性疾病、同种移植排斥或感染相关的疾病或紊乱的药物中的使用；优选地，肿瘤、神经退行性疾病、同种移植排斥或感染相关的疾病或紊乱是由热休克蛋白70（Hsp70）引起的疾病或紊乱。本发明的化合物是一类具有新颖结构和高活性的Hsp70抑制剂，解决了肿瘤耐药性的问题，增强了治疗肿瘤的效果，并为临床肿瘤治疗提供了新的医学策略。
• NEW UREA COMPOUND, MANUFACTURING METHOD AND APPLICATION THEREOF
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

  公开号：EP3085690A1

  公开（公告）日：2016-10-26

  The invention provides a compound of Formula I, an isomer, a pharmaceutically acceptable salt, or a solvate thereof, and use thereof in manufacture of a medicament for preventing and/or treating a drug-resistant tumor or disease or disorder caused by a drug-resistant bacterium, or use thereof in manufacture of a medicament for preventing and/or treating a tumor, a neurodegenerative disease, an allogeneic graft rejection, or an infection-associated disease or disorder; preferably, the tumor, neurodegenerative disease, allogeneic graft rejection, or infection-associated disease or disorder is a disease or disorder caused by Heat shock protein 70 (Hsp70). The compounds of the invention, which are a class of Hsp70 inhibitors having a novel structure and a high activity, solve the problem concerning drug resistance of tumors, enhance the effect of treating tumors, and provide a new medical strategy for treatment of tumors in clinic.

  本发明提供了一种式 I 的化合物、异构体、药学上可接受的盐或其溶解物，及其在制造预防和/或治疗耐药肿瘤或由耐药细菌引起的疾病或紊乱的药物中的用途，或其在制造预防和/或治疗肿瘤、神经退行性疾病、异体移植物排斥反应或感染相关疾病或紊乱的药物中的用途；优选地，肿瘤、神经退行性疾病、异体移植物排斥反应或感染相关疾病或紊乱是由热休克蛋白70（Hsp70）引起的疾病或紊乱。本发明化合物是一类结构新颖、活性较高的Hsp70抑制剂，解决了肿瘤耐药性问题，提高了治疗肿瘤的效果，为临床治疗肿瘤提供了一种新的医疗策略。
• Synthesis of 6‐R‐N‐aryl‐4‐(trichloromethyl)‐4H‐1,3,5‐oxadiazin‐2‐amines based on N‐(2,2,2‐trichloro‐1‐(3‐R‐thioureido)ethyl)carboxamides: Their spectral characteristics and molecular structure
  作者：Yelyzaveta R. Lomynoha、Pavlo V. Zadorozhnii、Vadym V. Kiselev、Aleksandr V. Kharchenko

  DOI：10.1002/jhet.4870

  日期：2024.10

  report the synthesis of a series of new 4H-1,3,5-oxadiazine derivatives. The method of their production is based on the dehydrosulfurization reaction of N-(2,2,2-trichloro-1-(3-R-thioureido)ethyl)carboxamides under the action of a mixture of iodine and triethylamine in DMF. A possible reaction mechanism has been proposed. The target products have been obtained in 58%–75% yield. The structure of the obtained

  在这项工作中，我们报道了一系列新的 4 H-1,3,5-噁二嗪衍生物的合成。其生产方法基于 N-（2,2,2-三氯-1-（3-R-硫脲基）乙基）甲酰胺在 DMF 中碘和三乙胺混合物作用下的脱氢硫化反应。已经提出了一种可能的反应机制。以 58%–75% 的收率获得目标产品。所得化合物的结构已通过 1H、13C NMR、IR 光谱数据和对 6-（叔丁基）-N-苯基-4-（三氯甲基）-4 H-1,3,5-噁二嗪-2-胺进行的 X 射线衍射分析得到证实。